Human Platelet Lysate as a Promising Growth-Stimulating Additive for Culturing of Stem Cells and other Cell Types

Shanskii, Ya. D.; Сергеева, Н. С.; Свиридова, И. К.; Kirakozov, M. S.; Кирсанова, В. А.; Ахмедова, С. А.; Antokhin, A. I.; Чиссов, В И

doi:10.1007/s10517-013-2298-7

Cited by 44 publications

(41 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelets lyse was triggered by either, freeze-thaw cycles (1 to 5), ultrasound (63) or chemical treatment (43). HPL presented a high growth factors and cytokines content (74)(75)(76)(77). HPL seemed to be better than FBS for ex vivo MSC expansion (52,72,78,79) since HPL-expanded MSC did not present telomerase shortening (68).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

et al. 2017

View full text Add to dashboard Cite

Although the biological properties of mesenchymal stem cells (MSC) are well-characterized in vitro, MSC clinical application is still far away to be achieved, mainly due to the need of xenogeneic substances for cell expansion, such as fetal bovine serum (FBS). FBS presents risks regarding pathogens transmissions and internalization of animal's proteins, which can unleash antigenic responses in patients after MSC implantation. A wide range of venous blood derivatives (VBD) has been reported as FBS substitutes showing promising results. Thus, the aim of this study was to conduct a systematic scoping review to analyze whether VBD are effective FBS substitutes for MSC ex vivo expansion. The search was performed in SciVerse Scopus TM , PubMed, Web of Science TM , BIREME, Cochrane library up to January 2016. The keywords were selected using MeSH and entry terms. Two independent reviewers scrutinized the records obtained considering specific inclusion criteria. The included studies were evaluated in accordance with a modified Arksey and O' Malley's framework. From 184 found studies, 90 were included. Bone marrow mesenchymal stem cells (BMMSC) were presented in most of these studies. Overall, VBD allowed for either, maintenance of MCS's fibroblast-like morphology, high proliferation, high colony-formation ability and maintenance of multipotency. Besides. MSC expanded in VBD supplements presented higher mitogen activity than FBS. VBD seems to be excellent xeno-free serum for ex vivo expansion of mesenchymal stem cells. However, an accentuated heterogeneity was observed between the carried out protocols for VBD isolation did not allowing for direct comparisons between the included studies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Blood contains several components as lipids (HDL, cholesterol), proteins, metabolites of uric acid, creatinine, and albumin; even as several ions: calcium, potassium, resulting from individual diet. Thus, plasm portion may have changes in biochemical composition (74). Growth factor's release profile of HPL and HS were contrasting.…”

Section: Discussionmentioning

confidence: 99%

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The greatest advantage of human serum-derived supplements is that they are non-xenogenic when used with human cell lines. However, potentially due to the limited availability and high prices, their applications are largely confined to the culture of human cells for therapeutic purposes, such as stem cells and mesenchymal stromal cells [35–37]. Numerous serum-free and animal-derived-component-free culture media are also available [38].…”

Section: Discussionmentioning

confidence: 99%

Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines

Fang

Chen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Fetal bovine serum (FBS) is depended upon by investigators as an indispensable supplement in cell and tissue culture systems. Due to increased demand and limited availability, the price of FBS has increased by greater than 300% in the past few years. In addition, there are ethical and scientific controversies about the collection and use of FBS in culture systems. In response to the shortage of FBS, many FBS alternative serum products have been developed. Although many have claimed comparable performance to FBS, their support of long-term cell growth and effects on cell phenotype have not been revealed. In this study, we examined the performances of six bovine calf serum-based FBS alternatives in six head and neck cell lines and compared them with FBS. The results indicate that some of these sera had growth promoting capabilities comparable or superior to that of FBS. Additionally, these alternative sera supported long-term (30 passages) growth of tested cells and exhibited plating efficiencies comparable to that of FBS. Cells cultured in alternative sera also exhibited comparable anchorage-independent growth and similar drug inhibition responses in FBS. Still, caution should be taken in choosing suitable sera given that changes in cell morphology and variations in chemotactic responses were noted for cells maintained in certain sera. These FBS alternatives are more readily available, cost less, and are associated with less ethical concerns, thus making them attractive alternatives to FBS in cell culture systems.

show abstract

“…A cocktail of growth factors, cytokines and mitogens stored in the α granules of platelets can be released following platelet activation by thrombin or the disruption of platelets by freeze thawing, with the latter approach being more attractive because the use of commercially available thrombin derived from bovine plasma is bypassed [649]. Hence, human PL may be an adequate non-xenogenic alternative to FBS in many cell culture systems that have been previously thought to be solely dependent on the presence of FBS [629,650]. …”

Section: Formulations Enriched With Endogenous Growth Factorsmentioning

confidence: 99%

Advancing biomaterials of human origin for tissue engineering

Chen

Liu

2016

Progress in Polymer Science

959

513

View full text Add to dashboard Cite

Biomaterials have played an increasingly prominent role in the success of biomedical devices and in the development of tissue engineering, which seeks to unlock the regenerative potential innate to human tissues/organs in a state of deterioration and to restore or reestablish normal bodily function. Advances in our understanding of regenerative biomaterials and their roles in new tissue formation can potentially open a new frontier in the fast-growing field of regenerative medicine. Taking inspiration from the role and multi-component construction of native extracellular matrices (ECMs) for cell accommodation, the synthetic biomaterials produced today routinely incorporate biologically active components to define an artificial in vivo milieu with complex and dynamic interactions that foster and regulate stem cells, similar to the events occurring in a natural cellular microenvironment. The range and degree of biomaterial sophistication have also dramatically increased as more knowledge has accumulated through materials science, matrix biology and tissue engineering. However, achieving clinical translation and commercial success requires regenerative biomaterials to be not only efficacious and safe but also cost-effective and convenient for use and production. Utilizing biomaterials of human origin as building blocks for therapeutic purposes has provided a facilitated approach that closely mimics the critical aspects of natural tissue with regard to its physical and chemical properties for the orchestration of wound healing and tissue regeneration. In addition to directly using tissue transfers and transplants for repair, new applications of human-derived biomaterials are now focusing on the use of naturally occurring biomacromolecules, decellularized ECM scaffolds and autologous preparations rich in growth factors/non-expanded stem cells to either target acceleration/magnification of the body's own repair capacity or use nature's paradigms to create new tissues for restoration. In particular, there is increasing interest in separating ECMs into simplified functional domains and/or biopolymeric assemblies so that these components/constituents can be discretely exploited and manipulated for the production of bioscaffolds and new biomimetic biomaterials. Here, following an overview of tissue auto-/allo-transplantation, we discuss the recent trends and advances as well as the challenges and future directions in the evolution and application of human-derived biomaterials for reconstructive surgery and tissue engineering. In particular, we focus on an exploration of the structural, mechanical, biochemical and biological information present in native human tissue for bioengineering applications and to provide inspiration for the design of future biomaterials.

show abstract

Human Platelet Lysate as a Promising Growth-Stimulating Additive for Culturing of Stem Cells and other Cell Types

Cited by 44 publications

References 7 publications

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines

Advancing biomaterials of human origin for tissue engineering

Contact Info

Product

Resources

About